Announcement on Voluntary Disclosure of the Approval of Marketing Application for Ivarmacitinib Hydrochloride Tablets for he Treatment of Severe Alopecia Areata

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of the Approval of Marketing Application for Ivarmacitinib Hydrochloride Tablets for he Treatment of Severe Alopecia Areata The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A